Transplantation osteoporosis

Current Osteoporosis Reports

Volumn 5, Issue 1, 2007, Pages 29-37

  Ebeling, Peter R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; RAPAMYCIN; RISEDRONIC ACID; SALCATONIN; SODIUM CHLORIDE; TACROLIMUS; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE DISEASE; BONE MARROW TRANSPLANTATION; BONE TURNOVER; CHRONIC RESPIRATORY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; ESTROGEN THERAPY; FRACTURE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HORMONE SUBSTITUTION; HUMAN; HYPOCALCEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LIVER DISEASE; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PANCREAS TRANSPLANTATION; PATIENT ASSESSMENT; PATIENT CARE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; SURVIVAL RATE; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

BONE DENSITY; DENSITOMETRY; DIPHOSPHONATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; OSTEOPOROSIS; RENAL OSTEODYSTROPHY; RESPIRATORY INSUFFICIENCY; TIME FACTORS; TRANSPLANTATION; VITAMIN D;

EID: 33947360250     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/BF02938620     Document Type: Review

References (61)

1. Cohen A, Sambrook P, Shane E: Management of bone loss after organ transplantation. J Bone Miner Res 2004, 19:1919-1932.
2. Cohen A, Ebeling PR, Sprague S, Shane E: Transplantation osteoporosis. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 6. Edited by Favus MJ. Washington, DC: American Society for Bone and Mineral Research; 2006:302-309.
3. Stehman-Breen CO, Sherrard DJ, Alem AM, et al.: Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000, 58:2200-2205.
4. Alem AM, Sherrard DJ, Gillen DL, et al.: Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000, 58:396-399.
5. Ball AM, Gillen DL, Sherrard D, et al.: Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002, 288:3014-3018.
6. Shane E, Mancini D, Aaronson K, et al.: Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure. Am J Med 1997, 103:197-207.
7. Monegal A, Navasa M, Guanabens N, et al.: Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 2001, 12:484-492.
8. Millonig G, Graziadei IW, Eichler D, et al.: Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 2005, 11:960-966.
9. Ninkovic M, Love SA, Tom B, et al.: High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001, 69:321-326.
10. Tschopp O, Boehler A, Speich R, et al.: Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am J Transplant 2002, 2:167-172.
11. Keilholz U, Max R, Scheibenbogen C, et al.: Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progenitor cell transplantation. Cancer 1997, 79:1617-1622.
12. Tauchmanova L, Selleri C, Rosa GD, et al.: High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 2002, 95:1076-1084.
13. Valimaki M, Kinnunen K, Volin L, et al.: A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999, 23:355-361.
14. Kananen K, Volin L, Laitinen K, et al.: Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 2005, 90:3877-3885.
15. Schulte C, Beelen D, Schaefer U, Mann K: Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int 2000, 11:344-353.
16. Epstein S: Post-transplantation bone disease: the role of immunosuppressive agents on the skeleton. J Bone Miner Res 1996, 11:1-7.
17. Ponticelli C, Aroldi A: Osteoporosis after organ transplantation [letter]. Lancet 2001, 357:1623.
18. McIntyre HD, Menzies B, Rigby R, et al.: Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant 1995, 9:20-24.
19. Stempfle HU, Werner C, Echtler S, et al.: Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. Transplant Proc 1998, 30:1132-1133.
20. Park KM, Hay JE, Lee SG, et al.: Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. Transplant Proc 1996, 28:1738-1740.
21. Goffin E, Devogelaer JP, Depresseux G, et al.: Osteoporosis after organ transplantation [letter]. Lancet 2001, 357:1623.
22. Monegal A, Navasa M, Guanabens N, et al.: Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001, 68:83-86.
23. Julian BA, Laskow DA, Dubovsky J, et al.: Rapid loss of vertebral bone density after renal transplantation. N Engl J Med 1991, 325:544-550.
24. Monier-Faugere M, Mawad H, Qi Q, et al.: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000, 11:1093-1099.
25. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al.: Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999, 14:456-463.
26. Wissing K M, Broeders N, Moreno-Reyes R, et al.: A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005, 79:108-115.
27. Grotz W, Nagel C, Poeschel D, et al.: Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001, 12:1530-1537.
28. Kovac D, Lindic J, Kandus A, Bren AF: Prevention of bone loss in kidney graft recipients. Transplant Proc 2001, 33:1144-1145.
29. Giannini S, Dangel A, Carraro G, et al.: Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001, 16:2111-2117.
30. Torres A, Garcia S, Gomez A, et al.: Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004, 65:705-712.
31. Schwarz CL, Mitterbauer CL, Heinze G, et al.: Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int 2004, 65:304-309.
32. Palmer SC, McGregor DO, Strippoli GFM: Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2005, CD005015. This important systematic review examines all current evidence for preventing bone disease in kidney transplant recipients. It concludes that bisphosphonates and calcitriol were more effective than nasal calcitonin and that large, placebo-controlled, randomized trials of bisphosphonates with fracture reduction as a primary end point are required.
33. Chiu MY, Sprague SM, Bruce DS, et al.: Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol 1998, 9:677-683.
34. Smets YFC, De Fijter JW, Ringers J, et al.: Long-term follow-up study on bone mineral density and fractures after simultaneous pancreas-kidney transplantation. Kidney Int 2004, 66:2070-2076.
35. Shane E, Papadopoulos A, Staron RB, et al.: Bone loss and fracture after lung transplantation. Transplantation 1999, 68:220-227.
36. Shane E, Addesso V, Namerow PB, et al.: Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004, 350:767-776. One of the best studies to date on prevention of bone loss after cardiac transplantation. It shows that both alendronate and calcitriol prevent bone loss in the first year after transplantation, compared with a historical control group.
37. Shane E, Rivas M, Staron RB, et al.: Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab 1996, 81:1740-1746.
38. Leidig-Bruckner G, Hosch S, Dodidou P, et al.: Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001, 357:342-347.
39. Sambrook P, Henderson NK, Keogh A, et al.: Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000, 15:1818-1824.
40. Henderson K, Eisman J, Keogh A, et al.: Protective effect of short-term calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res 2001, 16:565-571.
41. Stempfle HU, Werner C, Echtler S, et al.: Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 1999, 68:523-530.
42. Kapetanakis EI, Antonopoulos AS, Antoniou TA, et al.: Effect of long-term calcitonin administration on steroid-induced osteoporosis after cardiac transplantation. J Heart Lung Transplant 2005, 24:526-532.
43. Bianda T, Linka A, Junga G, et al.: Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 2000, 67:116-121.
44. Cohen A, Addesso V, McMahon DJ, et al.: Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. Transplantation 2006, 81:686-691. One of the best studies to date on prevention of bone loss after cardiac transplantation (follow-up to reference 36••). This follow-up study shows that bone mass is preserved in both groups in the second year off treatment, although a bone resorption marker was higher in the group that had received calcitriol. This finding emphasizes the need for close monitoring of patients after organ transplantation.
45. Ninkovic M, Skingle SJ, Bearcroft PW, et al.: Incidence of vertebral fractures in the first thee months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2000, 12:931-935.
46. Hommann M, Abendroth K, Lehmann G, et al.: Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. Transplant Proc 2002, 34:2296-2298.
47. Crawford, BAL, Kam C, Pavlovic J, et al.: Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006, 144:239-248. This randomized, double-blind study shows that five 4-mg zoledronate infusions within the first 9 months after liver transplantation prevent bone loss compared with calcium and vitamin D alone. The BMD benefit lasted 12 months at the total hip site, but not at other sites. Hypocalcemia was present in some patients receiving zoledronate.
48. Karasu Z, Kilic M, Tokat Y: The prevention of bone fractures after liver transplantation: experience with alendronate treatment. Transplant Proc 2006, 38:1448-1452.
49. Banfi A, Podesta M, Fazzuoli L, et al.: High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 2001, 92:2419-2428.
50. Lee WY, Cho SW, Oh ES, et al.: The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 2002, 87:329-335.
51. Kananen K, Volin L, Laitinen K, et al.: Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 2005, 90:3877-3885.
52. Ebeling P, Thomas D, Erbas B, et al.: Mechanism of bone loss following allogeneic and autologous hematopoietic stem cell transplantation. J Bone Miner Res 1999, 14:342-350.
53. Ebeling PR: Bone disease after bone marrow transplantation. In Bone Disease of Organ Transplantation. Edited by Compston J, Shane E. New York: Academic Press; 2005:339-352.
54. Lee WY, Kang MI, Baek KH, et al.: The skeletal site-differential changes in bone mineral density following bone marrow transplantation: 3-year prospective study. J Korean Med Sci 2002, 17:749-754.
55. Gandhi MK, Lekamwasam S, Inman I, et al.: Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol 2003, 121:462-468.
56. Ebeling PR: Is defective osteoblast function responsible for bone loss from the proximal femur despite pamidronate therapy? J Clin Endocrinol Metab 2005, 90:4414-4416.
57. Tauchmanova L, De Rosa G, Serio B, et al.: Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer 2003, 97:2453-2461.
58. Tauchmanova L, Selleri C, Esposito M, et al.: Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 2003, 14:1013-1019.
59. Tauchmanova L, Ricci P, Serio B, et al.: Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2005, 90:627-634.
60. Grigg AP, Shuttleworth P, Reynolds J, et al.: Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2006, 91:3835-3843. This prospective, randomized study of monthly 90-mg pamidronate infusions for 12 months showed a significant reduction in bone loss at all sites compared with calcium and calcitriol alone. However, after patients were off pamidronate for 12 months, only the BMD benefit at the total hip was maintained. Importantly, the benefits of pamidronate therapy were restricted to those receiving moderate to high prednisolone doses or prolonged cyclosporine therapy for graft-versus-host disease.
61. D'Souza AB, Grigg AP, Szer J, Ebeling PR: Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Intern Med J 2006, 36:600-603.